Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Immutep Limited
  6. Summary
    IMM   AU000000IMM6

IMMUTEP LIMITED

(IMM)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
0.53 0.52 0.52 0.55 0.54 Last
816820 630316 1090321 1504140 1516645 Volume
-0.93% -1.89% 0.00% +5.77% -1.82% Change
Estimated financial data (e)
Sales 2022 8,86 M 6,58 M 6,58 M
Net income 2022 -31,3 M -23,3 M -23,3 M
Net Debt 2022 6,40 M 4,75 M 4,75 M
P/E ratio 2022 -12,2x
Yield 2022 -
Sales 2023 28,6 M 21,2 M 21,2 M
Net income 2023 -4,72 M -3,50 M -3,50 M
Net cash position 2023 89,0 M 66,0 M 66,0 M
P/E ratio 2023 -117x
Yield 2023 -
Capitalization 459 M 341 M 341 M
EV / Sales 2022 52,6x
EV / Sales 2023 13,0x
Nbr of Employees -
Free-Float 85,2%
More Financials
Company
Immutep Limited is an Australia-based biotechnology company. The Company is engaged in the development of LAG-3 immunotherapeutic products, an immunotherapy for cancer and autoimmune disease. The Company has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical... 
More about the company
Ratings of Immutep Limited
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C
More Ratings
All news about IMMUTEP LIMITED
10/13IMMUTEP : Corporate Connect - A Truly Undervalued Company
PU
10/12IMMUTEP : 2021 Annual General Meeting and Key Dates
PU
10/04IMMUTEP : to Present Data, Trial Design of Clinical Studies for Cancer Treatments During M..
MT
10/03IMMUTEP : to present Phase II TACTI-002 data at SITC 2021
PU
10/01IMMUTEP : to Present Phase II TACTI-002 Data at SITC 2021
AQ
09/29IMMUTEP : Receives $2.49 Million as R&D Tax Incentive from French Government
MT
09/29IMMUTEP : Receives A$3.4 million R&D Tax Incentive from French Government
AQ
09/29IMMUTEP : Receives A$3.4 million R&D Tax Incentive from French Government (Form 6-K)
PU
09/28IMMUTEP : Receives $2.5 Million Tax Incentive from France
MT
09/28IMMUTEP : Receives A$3.4 million R&D French Tax Incentive
PU
09/27IMMUTEP : to Present at Healthcare Investor Conferences
PU
09/21Immutep to Present Final Overall Survival Data FromáPhase IIb AIPAC as a Late Breaking ..
GL
09/21Immutep to Present Final Overall Survival Data from Phase IIb AIPAC as a Late Breaking ..
CI
09/20IMMUTEP : Maxim Group - The Case for LAG-3 is Building
PU
09/20IMMUTEP : ESMO 2021 – INSIGHT - Stratum D Poster
PU
More news
News in other languages on IMMUTEP LIMITED
10/04Immutep présentera des données et la conception d'essais cliniques pour le traitement d..
09/28Immutep reçoit une incitation fiscale de 2,5 millions de dollars de la France
09/01Immutep achève le recrutement de patients dans la phase 2 de la partie B de l'étude sur..
09/01Immutep termine le recrutement et le dosage dans l'essai de phase 2 de la bithérapie co..
08/31Le partenaire chinois d'Immutep élargit son portefeuille d'essais cliniques pour un méd..
More news
Analyst Recommendations on IMMUTEP LIMITED
More recommendations
Chart IMMUTEP LIMITED
Duration : Period :
Immutep Limited Technical Analysis Chart | IMM | AU000000IMM6 | MarketScreener
Technical analysis trends IMMUTEP LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 0,54 AUD
Average target price 1,18 AUD
Spread / Average Target 118%
EPS Revisions
Managers and Directors
Marc Voigt Chief Executive Officer, CFO & Executive Director
David Fang Finance Director & Assistant Secretary
Russell John Howard Non-Executive Chairman
FrÚdÚric Triebel Chief Scientific & Medical Officer
Deanne Miller COO, Co-Secretary & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
IMMUTEP LIMITED30.12%341
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414